Transce3nd’s Royalty Pharma RPRX Stock Holding History

Transce3nd’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,203	Closed	-$79.4K	–	924
2025 Q2	$79.4K	Hold	2,203	–	–	0.03%	225
2025 Q1	$68.6K	Sell	2,203 -204	-8%	-$6.47K	0.03%	236
2024 Q4	$61.4K	Buy	+2,407	New	+$63.8K	0.02%	334

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Transce3nd's RPRX Position: Q3 2025 in Review

Transce3nd sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 2,203 shares — an estimated $79.4K sold.

Transce3nd first reported a position in RPRX in Q4 2024 and held it in 3 quarters. The position peaked at $79.4K in Q2 2025. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

Transce3nd reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 2,203 Royalty Pharma shares in Q3 2025, an estimated $79.4K.
Transce3nd first reported a position in Royalty Pharma in Q4 2024 and held it in 3 quarters.
Transce3nd's Royalty Pharma position peaked at $79.4K in Q2 2025.
488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.